Used for topical treatment of actinic keratoses
Alembic Pharmaceuticals today announced that its wholly owned subsidiary, Aleor Dermaceuticals has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Diclofenac Sodium Topical Gel, 3%.The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Solaraze Topical Gel, 3%, of fougera Pharmaceuticals Inc. (Fougera).Diclofenac Sodium Topical Gel, 3% is indicated for the topical treatment of actinic keratoses. Sun avoidance is indicated during therapy. Diclofenac Sodium Topical Gel, 3% has an estimated market size of. US$10 million for twelve months ending Mar., 2022 according to IQVIA.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
 Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
- Over 30 premium stories daily, handpicked by our editors 


Complimentary Access to The New York Times
- News, Games, Cooking, Audio, Wirecutter & The Athletic 
Business Standard Epaper
- Digital replica of our daily newspaper — with options to read, save, and share 


Curated Newsletters
- Insights on markets, finance, politics, tech, and more delivered to your inbox 
Market Analysis & Investment Insights
- In-depth market analysis & insights with access to The Smart Investor 


Archives
- Repository of articles and publications dating back to 1997 
Ad-free Reading
- Uninterrupted reading experience with no advertisements 


Seamless Access Across All Devices
- Access Business Standard across devices — mobile, tablet, or PC, via web or app 


